دورية أكاديمية
أعرض في EDS

Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study.

التفاصيل البيبلوغرافية
العنوان: Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study.
المؤلفون: Takahara N; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan., Isayama H; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. isayama-tky@umin.ac.jp., Nakai Y; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan., Sasaki T; Department of Gastroenterology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan., Ishigaki K; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan., Saito K; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan., Akiyama D; Department of Gastroenterology, JR Tokyo General Hospital, Tokyo, Japan., Uchino R; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan., Mizuno S; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan., Yagioka H; Department of Gastroenterology, Tokyo Metropolitan Police Hospital, Tokyo, Japan., Kogure H; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan., Togawa O; Department of Gastroenterology, Kanto Central Hospital, Tokyo, Japan., Matsubara S; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan., Ito Y; Department of Gastroenterology, Japanese Red Cross Medical Center, Tokyo, Japan., Toda N; Department of Gastroenterology, Mitsui Memorial Hospital, Tokyo, Japan., Tada M; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan., Koike K; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
المصدر: Investigational new drugs [Invest New Drugs] 2017 Jun; Vol. 35 (3), pp. 269-276. Date of Electronic Publication: 2017 Jan 26.
نوع المنشور: Journal Article; Multicenter Study
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE
أسماء مطبوعة: Publication: New York : Springer
Original Publication: Boston : M. Nijhoff, 1983-
مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Biliary Tract Neoplasms/*drug therapy , Cisplatin/*therapeutic use , Deoxycytidine/*analogs & derivatives , Oxonic Acid/*therapeutic use , Tegafur/*therapeutic use, Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cisplatin/adverse effects ; Deoxycytidine/adverse effects ; Deoxycytidine/therapeutic use ; Disease-Free Survival ; Drug Combinations ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Oxonic Acid/adverse effects ; Retrospective Studies ; Tegafur/adverse effects ; Young Adult ; Gemcitabine
مستخلص: Objective This study aimed to compare the safety and efficacy of the combination therapy of gemcitabine and S-1 (GS) versus gemcitabine and cisplatin (GC) in patients with advanced biliary tract cancer (BTC). Methods In this multicenter retrospective cohort study, a total of 212 patients with advanced BTC receiving GS (n = 125) or GC (n = 87) between July 2006 and August 2015 were analyzed. The primary endpoint was overall survival (OS). The secondary endpoints were progression-free survival (PFS), objective tumor response, and safety. Results Patient characteristics were well balanced between the two groups, except for tumor size (the baseline sum of the largest diameter of the tumor: 6.3 cm in the GS group vs. 8.6 cm in the GC group, p = 0.01). Although the response rate was higher in the GS group than in the GC group (28.8% vs. 10.3%, p = 0.01), the median PFS and OS were comparable between the two groups (PFS of 5.6 vs. 7.6 months, p = 0.74; OS of 12.4 vs. 9.2 months, p = 0.20, respectively). Stomatitis and skin rash were more frequently observed in the GS group, whereas anemia, thrombocytopenia, nausea, and renal toxicity were more commonly observed in the GC group. Conclusion This study demonstrates that GS and GC are similar with regard to their safety and efficacy in patients with advanced BTC. GS could serve as an alternative treatment for advanced BTC as a first-line chemotherapy.
References: N Engl J Med. 2010 Apr 8;362(14):1273-81. (PMID: 20375404)
Cancer Chemother Pharmacol. 2011 Apr;67(4):847-53. (PMID: 20563811)
J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16. (PMID: 10655437)
Cancer. 2015 Sep 15;121(18):3290-7. (PMID: 26052689)
Cancer Chemother Pharmacol. 2013 Apr;71(4):973-9. (PMID: 23355041)
Cancer Chemother Pharmacol. 2010 May;65(6):1101-7. (PMID: 19707761)
Br J Cancer. 2010 Aug 10;103(4):469-74. (PMID: 20628385)
Br J Cancer. 2016 Apr 12;114(8):881-8. (PMID: 27031848)
Cancer Chemother Pharmacol. 2011 Jun;67(6):1429-34. (PMID: 20811895)
Jpn J Clin Oncol. 2016 Apr;46(4):385-8. (PMID: 27025903)
BMC Cancer. 2016 Mar 15;16:222. (PMID: 26979596)
J Hepatobiliary Pancreat Surg. 2009;16(1):1-7. (PMID: 19110652)
Oncology. 2009;77(1):71-4. (PMID: 19556812)
Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774)
Cancer Chemother Pharmacol. 2015 Apr;75(4):711-8. (PMID: 25630414)
Cancer Chemother Pharmacol. 2008 Oct;62(5):849-55. (PMID: 18214482)
Oncology. 2009;76(2):126-32. (PMID: 19158445)
Cancer Sci. 2013 Sep;104(9):1211-6. (PMID: 23763511)
Ann Oncol. 2014 Dec;25(12):2328-38. (PMID: 24769639)
World J Gastroenterol. 2014 Dec 28;20(48):18452-7. (PMID: 25561816)
فهرسة مساهمة: Keywords: Biliary tract cancer; Chemotherapy; Cisplatin; Gemcitabine; Retrospective study; S-1
المشرفين على المادة: 0 (Antineoplastic Agents)
0 (Drug Combinations)
0W860991D6 (Deoxycytidine)
150863-82-4 (S 1 (combination))
1548R74NSZ (Tegafur)
5VT6420TIG (Oxonic Acid)
Q20Q21Q62J (Cisplatin)
0 (Gemcitabine)
تواريخ الأحداث: Date Created: 20170127 Date Completed: 20180321 Latest Revision: 20221207
رمز التحديث: 20221213
DOI: 10.1007/s10637-017-0430-7
PMID: 28124197
قاعدة البيانات: MEDLINE
الوصف
تدمد:1573-0646
DOI:10.1007/s10637-017-0430-7